RAS mutation specific survival in patients with metastatic colorectal cancer treated with trifluridine/tipiracil

被引：0
|
作者：
Grell, Peter
Batko, Stanislav
Pirsthuk, Alina
Borilova, Simona
Polachova, Katerina
Mazuchova, Blanka
Tomasek, Jiri
Fabian, Pavel
Berkovcova, Jitka
Bardelcik, Miroslav
Obermannova, Radka
Buchler, Tomas
Kiss, Igor
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-2370-7650-2700; 3282-206-4957-326-5009-5024-5025; 3282-206-4957-326-5009-2386; 10; 2; 38092-25821; 38092-18412; 38092-18849; 8; 4;
D O I：
10.1200/JCO.2024.42.3_suppl.197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
    Martinez-Perez, Julia
    Carmen Riesco-Martinez, M.
    Garcia-Carbonero, Rocio
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650
  • [22] Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil
    Skuja, Elina
    Gerina-Berzina, Aija
    Hegmane, Alinta
    Zvirbule, Zanete
    Vecvagare, Eva
    Purkalne, Gunta
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (05) : 699 - 702
  • [23] Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
    Cheung, W. Y.
    Kavan, P.
    Dolley, A.
    CURRENT ONCOLOGY, 2020, 27 (05) : E451 - E458
  • [24] Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
    Patel, Anuj K.
    Barghout, Victoria
    Yenikomshian, Mihran A.
    Germain, Guillaume
    Jacques, Philippe
    Laliberte, Francois
    Duh, Mei S.
    ONCOLOGIST, 2020, 25 (01): : E75 - E84
  • [25] Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
    Kamiimabeppu, Daisaku
    Osumi, Hiroki
    Shinozaki, Eiji
    Ooki, Akira
    Wakatsuki, Takeru
    Yoshino, Koichiro
    Sato, Taro
    Nakayama, Izuma
    Ogura, Mariko
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [26] Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
    Ozet, Ahmet
    Dane, Faysal
    Aykan, Nuri Faruk
    Yalcin, Suayib
    Evrensel, Turkkan
    Ozkan, Metin
    Karabulut, Bulent
    Ormeci, Merve Nur
    Atasev, Ozan
    Vidot, Loick
    Cicin, Irfan
    FUTURE ONCOLOGY, 2022, 18 (29) : 3267 - 3276
  • [27] Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer
    Victorino, Ana Paula Ornellas S.
    Meton, Fernando
    Mardegan, Luciana
    Festa, Juliana
    Piranda, Diogo N.
    Araujo, Kelly Borges
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
  • [28] Trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer treatment
    Michel, Patryk S.
    Jankowski, Marek
    Sigorski, Dawid
    Kubiatowski, Tomasz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06):
  • [29] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [30] The onset of grade ≥ 3 neutropenia at the first cycle is associated with longer overall survival in metastatic colorectal cancer patients treated with trifluridine/tipiracil
    Giuliani, J.
    Bonetti, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 31 - 31
12345